Canadian Federal Court Grants Decision to Ranbaxy on Pfizer’s Atorvastatin Patent

Ranbaxy Laboratories Limited has recently announced that the Federal Court of Canada today handed down a favorable decision in the company’s case against Pfizer by finding invalid Pfizer’s Canadian atorvastatin patent CA 2,021,546. Atorvastatin is a cholesterol- lowering drug which is marketed by Pfizer as Lipitor(R).